|
|
 |
|
Viewing report
|
|
|
|
CNS Drug Discoveries: What The Future Holds Sleep Disorders Chapter
Espicom Business Intelligence Ltd, Nov 2006, Pages: 82
This chapter of CNS Drug Discoveries focuses on the developments in the insomnia market and the substantial changes beginning to take place.
The insomnia market is a maturing market and we believe the landscape will change dramatically over the next five years as the market enters a transition phase and becomes more fragmented. We forecast it will grow to nearly US$6 billion by 2012 driven by a number of factors including the launch of new formulations, new drug classes, patient dynamics (ageing patient population) and changes in the way insomnia is treated.
Sleep disorders cover a range of problems, the best known types being insomnia, sleep apnoea and restless legs syndrome. Insomnia is the most prevalent sleep disorder and it is estimated to affect over 37 million US citizens and over 100 million people worldwide with approximately 25% of elderly people and 15% of the general population suffering from the condition. Studies suggest that less than 20% of insomniacs seek help and less than 20% of sufferers are prescribed a medication from their doctor.
Global insomnia market
Approximately US$2.4 billion is currently spent on hypnotics and sedatives in the treatment of insomnia, the 10th largest segment of CNS drug sales. The global market for insomnia drugs is unevenly distributed. In 2005, the US insomnia market accounted for 66% of the global market compared to 24% in Europe and 10% in the rest of world (largely Japan). This is mainly due to the pricing differential between the European and the US market.
GABA-A receptor agonists (non-benzodiazepines) continue to remain the cornerstone for the treatment of both acute and chronic insomnia. However, the launch of several new products over the next 3 years will help to increase patient awareness, particularly in the elderly.
The full report covers six key CNS therapy areas; the information provided here is specific to just one chapter. For information on the full report, please search our Website. This chapter is available for purchase separately.
|
|
|
|
